These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 9420050)

  • 41. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.
    Jones RN; Barry AL; Thornsberry C; Gerlach EH; Fuchs PC; Gavan TL; Sommers HM
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro activity of the tricyclic beta-lactam GV104326.
    Wise R; Andrews JM; Brenwald N
    Antimicrob Agents Chemother; 1996 May; 40(5):1248-53. PubMed ID: 8723475
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
    Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
    J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
    Pillar CM; Aranza MK; Shah D; Sahm DF
    J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative in vitro activity of meropenem versus other extended-spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 North American centers.
    Pitkin DH; Sheikh W; Nadler HL
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S238-48. PubMed ID: 9126699
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro and in vivo antibacterial activities of meropenem, a new carbapenem antibiotic.
    Harabe E; Kawai Y; Kanazawa K; Otsuki M; Nishino T
    Drugs Exp Clin Res; 1992; 18(2):37-46. PubMed ID: 1644010
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro antibacterial activity and beta-lactamase stability of the new carbapenem SM-7338.
    Sumita Y; Inoue M; Mitsuhashi S
    Eur J Clin Microbiol Infect Dis; 1989 Oct; 8(10):908-16. PubMed ID: 2512140
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M; Browne FA; Jacobs MR; Appelbaum PC
    Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro and in vivo activities of SCE-2787, a new parenteral cephalosporin with a broad antibacterial spectrum.
    Iwahi T; Okonogi K; Yamazaki T; Shiki S; Kondo M; Miyake A; Imada A
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1358-66. PubMed ID: 1510428
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro activity of BAY 12-8039, a new fluoroquinolone.
    Woodcock JM; Andrews JM; Boswell FJ; Brenwald NP; Wise R
    Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of susceptibility to extended-spectrum beta-lactam antibiotics and ciprofloxacin among gram-negative bacilli isolated from intensive care units.
    Liu PY; Lau YJ; Hu BS; Shyr JM; Shi ZY; Tsai WS; Lin YH; Tseng CY
    Diagn Microbiol Infect Dis; 1995 Jul; 22(3):285-91. PubMed ID: 8565418
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
    Bouchillon SK; Hoban DJ; Johnson BM; Johnson JL; Hsiung A; Dowzicky MJ;
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative in vitro activity of CGP 31608, a new penem antibiotic.
    Eliopoulos GM; Wennersten C; Reiszner E; Moellering RC
    Antimicrob Agents Chemother; 1987 Aug; 31(8):1188-93. PubMed ID: 3498437
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.
    Gales AC; Jones RN
    Diagn Microbiol Infect Dis; 2000 Jan; 36(1):19-36. PubMed ID: 10744364
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1995). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Takanashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Kosakai N; Yamaguchi K; Matsumoto T; Kashitani F; Tanaka M
    Jpn J Antibiot; 1997 Mar; 50(3):219-50. PubMed ID: 9575353
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents.
    Sader HS; Jones RN; Stilwell MG; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):181-6. PubMed ID: 16105562
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates.
    Tanaka M; Yamazaki E; Chiba M; Yoshihara K; Akasaka T; Takemura M; Sato K
    Antimicrob Agents Chemother; 2002 Mar; 46(3):904-8. PubMed ID: 11850285
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative in vitro activity of piperacillin/tazobactam against gram-negative bacilli.
    Liebowitz LD; Klugman KP
    S Afr Med J; 1996 Oct; 86(10):1276-80. PubMed ID: 8955735
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
    Pucci MJ; Cheng J; Podos SD; Thoma CL; Thanassi JA; Buechter DD; Mushtaq G; Vigliotti GA; Bradbury BJ; Deshpande M
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1259-67. PubMed ID: 17242152
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.
    Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA;
    Diagn Microbiol Infect Dis; 2001; 40(1-2):51-7. PubMed ID: 11448564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.